anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE OF REVIEW: This review explores the epidemiology, clinical traits, and diagnosis of Transcatheter Aortic Valve Replacement-Associated Infective Endocarditis (TAVR-IE) and mitral transcatheter edge-to-edge repair infective endocarditis (TEER-IE), focusing on a multimodal imaging approach. It addresses the rising prevalence of TAVR and TEER, emphasizing the need to understand long-term complications and clinical consequences, which poses significant challenges despite advancements in valve technology.
RECENT FINDINGS: Studies report a variable incidence of TAVR-IE and TEER-IE influenced by diverse patient risk profiles and procedural factors. Younger age, male gender, and certain comorbidities emerge as patient-related risk factors. Procedure-related factors include intervention location, valve type, and technical aspects. Microbiologically, Staphylococcus aureus, Viridans Group Streptococcus, and Enterococcus are frequently encountered pathogens. TAVR-IE and TEER-IE diagnosis involves a multimodal imaging approach due to limitations in echocardiography. Blood cultures and imaging aid identification, with Fluorescence in situ hybridization is showing promise. Treatment encompasses medical management with antibiotics and, when necessary, surgical intervention. The management approach requires a multidisciplinary "Endocarditis Team." This review underscores the need for continued research to refine risk prediction, enhance diagnostic accuracy, and optimize management strategies for TAVR-IE, considering the evolving landscape of transcatheter interventions.
PURPOSE: We propose the utilization of patient-specific concentric-tube robots (CTRs) whose designs are optimized to enhance their volumetric reachability of the renal stone, thus reducing the morbidities associated with percutaneous nephrolithotomy procedures. By employing a nested optimization-driven scheme, this work aims to determine a single surgical tract through which the patient-tailored CTR is deployed. We carry out a sensitivity analysis on the combined percutaneous access and optimized CTR design with respect to breathing-induced excursion of the kidneys based on preoperative images. Further, an investigation is also performed of the appropriateness and effectiveness of the percutaneous access provided by the proposed algorithm compared to that of an expert urologist.
METHODS: The method is based on an ellipsoidal approximation to the renal calculi and a grid search over candidate skin areas and available renal calyces using an anatomically constrained kinematic mapping of the CTR. Percutaneous access is selected for collision-free CTR deployment to the centroid of the stones with minimal positional error at the renal calyx. Further optimization of the CTR design results in a robot tailored to the therapeutic anatomical features of each clinical case. The study examined 14 sets of clinical data of PCNL patients, analyzing stone reachability using preoperative images and breathing-induced motions of the kidney. An experienced urologist qualitatively assessed the adequacy of percutaneous access generated by the algorithm.
RESULTS: An assessment conducted by an expert urologist found that the percutaneous accesses produced by the proposed approach were found to be comparable to those chosen by the expert surgeon in most clinical cases. The simulated results demonstrated a mean volume coverage of 81.6 % ± 19.6 %  for static anatomy and 63.7 % ± 27.7 %  and 69.0 % ± 25.4 %  when considering a 1 cm excursion of the kidney in the craniocaudal directions due to respiration or tool-tissue interaction.
CONCLUSION: The optimization-driven scheme for determining a single tract surgical plan, coupled with the use of a patient-specific CTR, shows promising results for improving percutaneous access in PCNL procedures. This approach clearly shows the potential for enhancing the quality and suitability of percutaneous accesses, addressing the challenges posed by staghorn and non-staghorn stones during PCNL procedures. Further research involving clinical validation is necessary to confirm these findings and explore the potential clinical benefits of the approach.
All participants (both the intervention and control condition) will receive to 11 weekly short (about 2-3 minutes) Teaching Kitchen Outreach (TKO) videos. Recipe specific groceries will be delivered to participants' homes by a third party grocery delivery company, or will be available for pickup at a central location(s). These recipes reflect foods that can be purchased with SNAP and WIC and include tested meals and snacks that were developed and evaluated in person in Parks and Recreation after-school programming.
Cardiac microvascular endothelial cells (CMECs) are important cells surrounding the cardiomyocytes in the heart that maintain microenvironment homeostasis. Salvianic acid A sodium (SAAS) has been reported to prevent myocardial infarction (MI) injury. However, the role of SAAS on CMEC proliferation remains unclear. CEMCs exposed to oxygen glucose deprivation (OGD) were used to explore the angiogenic abilities of SAAS. In vivo, C57BL/6 mice were divided into three groups: sham, MI and SAAS + MI groups. Compared to OGD group, SAAS led to a reduction in the apoptotic rate and an increase of the proliferation in vitro. Additionally, SAAS increased the protein levels of Bcl2, HIF-1α and vascular endothelial growth factor (VEGF) with the reduction of Bax. In terms of the specific mechanisms, SAAS might inhibit HIF-1α ubiquitination and enhance the HIF-1α/VEGF signalling pathway to increase CMEC proliferation. Furthermore, SAAS increased the density of vessels, inhibited myocardial fibrosis and improved cardiac dysfunction in vivo. The present study has revealed that SAAS could potentially be used as an active substance to facilitate CMEC proliferation post-MI.
The invention discloses a method for treating acute pelvic inflammatory disease. The method is a method for treating chronic pelvic inflammatory disease by using traditional Chinese medicine. According to the invention, 18g of salvia miltiorrhiza, 15g of red peony root, 12g of banksian rose, 9g of peach seed, 30g of honeysuckle flower, 30g of dandelion, 12g of tuckahoe, 9g of peony tree root bark, and 9g of raw rehmannia rhizome are adopted. When a patient suffers from pain, 9g of Yanhusuo tuber is added. Some patient suffers from qi stagnation caused by cold obstruction, and meridian-warming, cold-dispelling, qi-promoting, and blood-circulation-activating effects are needed. Therefore, a cassia twig and tuckahoe decoction is needed. For patient with qi deficiency, 15g of pilose asiabell root, 9g of largehead atractylodes rhizome, and 15g of Mongolian milkvetch root are added. When in use, the medicine materials are placed into earthenware or a casserole; the materials are soaked for 10min by using cold water immersing the materials; the materials are decocted for 5-8min by using a big fire, and are decocted for 20min by using a mild fire; and the decoction is cooled to warm, and is orally taken. 1 preparation is taken per day, and is divided in two parts which are respectively taken in the morning and in the evening.
Formocresol is a commonly used medicament in dentistry. The currently available fromocresol is of full strength and the international agency for cancer research as an affiliate of World Health Organisation recommends the use of minimum concentration of formaldehyde. This initiated us to do research to formulate a new gel form with minimum concentration of formaldehyde. We have done an in vitro study and our results have shown that this can be recommended as a medicament. We also found that the material is user friendly as it prevents formaldehyde vapour fumes while applying. The usage of 1-in-5 dilution of Buckley's formocresol is recommended is denistry, that does better in get form. The dilution should be performed in the local pharmacy to ensure accuracy. Recent research by King sr,(2002) has indicated that a minority of pediatric dentists use dilute formocresol because it is not available commercially.
The invention provides a medicinal liquor with weight loss and fat reduction effects. The preparation of the medicinal liquor is simple. The materials of medicinal liquor comprise lotus seeds, lotus roots, lotus flowers, bighead atractylodes rhizome, codonopsis pilosula, hawthorns and baijiu. The medicinal liquor has a simple processing method. The main effective ingredients are all natural food materials and traditional Chinese herbal medicines, wherein the effects of the ingredient are promoted through the preparation of the medicinal liquor with the ingredients. The medicinal liquor has obvious weight loss and fat reduction effects, and can effectively alleviate the symptoms of obesity, digestive failure, high blood fat and the like. The medicinal liquor prepared accordingly has no special requirement for storage, thus being suitable for being served as drinks to the public, in particular to people who want to lose weight, keep fit and reduce fat.
PURPOSE:To obtain the title low irritable tack agent excellent in applicability by copolymerization between an 8C alkyl acrylate and specific styrene macromonomer at specified proportion followed by, where appropriate, further copolymerization of (meth)acrylic acid at specified proportion. CONSTITUTION:The objective tack agent made from (A) 100 pts.wt. of an alkyl acrylate produced from acrylic acid and an 8C alkyl alcohol, (B) 1-25 pts.wt. of styrene macromonomer with a molecular weight of 1000-30000, and (C) 0-3 pts.wt. of (meth)acrylic acid. The present tack agent, even if applied on sites with frequent motion, will give adequate tackiness; furthermore, there is no concern for causing skin irritation with no stretched feeling at applied sites on the skin. The present tack agent is used in medical tapes for the application on biological membranes such as the skin and mucous membrane or external cataplasms such as adhesive plasters.
Attention Deficit/ Hyperactivity Disorder (ADHD) is a prevalent childhood psychiatric condition affecting 5-10% of children worldwide. ADHD persists into adolescence in 70-80% of those diagnosed in childhood. In adolescence, ADHD is associated with impairments in academic, social, and emotional functioning, as well as with elevated rates of psychiatric comorbidities, substance abuse, and antisocial behaviour.

Medication is currently the mainstay treatment for adolescents with ADHD. Although medication is an efficacious treatment for core ADHD symptoms, it does not directly address the associated academic, social, emotional and behavioural impairments. Overcoming these would require skills in organization, time management, problem solving, emotional modulation, stress management and interpersonal rapport. While these skills are important in childhood, they become particularly indispensable as the child enters adolescence and is expected to function more autonomously. However, little is known about the efficacy of psychosocial treatments targeting such skills for adolescents with ADHD, and there are few psychosocial treatment options available to these adolescents in the community.

The purpose of the study will be to evaluate the efficacy of a novel integrative therapy that uses cognitive-behavioural approaches to foster the development of these skills in adolescents with ADHD. Adolescents with ADHD, ages 13-17, will be randomly assigned to either 12 sessions of manualized group cognitive behavioural and skills training therapy (CBT+S) or to 12 sessions of manualized supportive group therapy (SGT). The CBT+S sessions will focus on acquisition of skills targeting the common functional deficits of adolescents with ADHD, with the modules covering psychoeducation, goal attainment, organization, time management, focus training and distractibility reduction, impulse control, study skills, stress management, cognitive restructuring, anger management, social skills, and self-esteem. A coach will call each participant twice a week to help implement CBT+S strategies in daily life. Supportive group therapy (SGT) for the adolescents will focus on increasing understanding of ADHD, sharing experiences, and fostering a network of support. Calls from a coach will deal with participant-elicited issues. Parents of all adolescents will participate in parallel 6-session support groups similar to SGT and focused on psychoeducation, sharing and support. Treatment effects will be evaluated after 12 weeks of treatment. Maintenance of treatment benefits will be evaluated after 4 and 8 months of follow up. A treatment as usual group will be used to control for repeated measurements.
Non-invasive electrical spinal cord stimulation will be performed using surface electrodes placed over the skin of the neck. Biphasic rectangular pulses of 1 millisecond per phase duration will be delivered with a 10 kiloHertz overlapping frequency and between 20-120 Hertzz burst frequency. Non-invasive electrical spinal cord stimulation will be paired with Activity Based Rehabilitation sessions. Stimulation plus rehabilitation sessions will be three times per week, 90 minutes per session for six weeks (total of 18 sessions).
<P>PROBLEM TO BE SOLVED: To solve conventional problems of falling of a disk-shaped portion and inconvenience when peeling.  <P>SOLUTION: This mount 1 for fixing patch sheets has a peel-off layer to which an adhesive face of the patch sheet 2 is peelably stuck, on its one surface, and is formed into a long rectangular shape so that a plurality of patch sheets 2 are alignedly stuck to the peel-off layer. A patch area S of each patch sheet 2 is formed with cuts 3a and 3b traversing each patch area S and reaching the edge. Each of the cuts 3a and 3b includes a linear portion 30 and an arcuate portion 31 extending half around the center C of the patch area S of the patch sheet 2. The arcuate portion 31 is adapted to be cut open and raised when being folded along the linear portion 30.  <P>COPYRIGHT: (C)2010,JPO&INPIT
In a meta-analysis of 5 trials, the addition of gemtuzumab ozogamicin (GO) to intensive induction chemotherapy led to a survival benefit in patients with core-binding factor (CBF) acute myeloid leukemia (AML). Given the heterogeneous incorporation of GO in clinical trials, the ideal dose and schedule remains unclear. We conducted a single-center retrospective analysis to compare outcomes of patients with CBF-AML treated with intensive induction chemotherapy, with or without a single dose of GO 3 mg/m2, during induction only. We included 87 patients (GO=32, control=55). The composite complete remission (cCR) rate was higher in the control group (93%) compared to the GO group (82%) (p<0.001). The rate of measurable residual disease (MRD) negative cCR, by flow cytometry, was similar between both groups. There were no significant differences between the two groups in terms of toxicity. The 3-year relapse-free survival (RFS) for both groups was similar (71% vs 68%, p=0.5). The 3-year overall survival (OS) for the GO group was 68%, compared to 66% for the control group (p=0.9).In multivariable analysis, age and MRD positive status were risk factors for inferior outcomes. We find that survival of patients with CBF-AML is favorable in the real-world setting. The addition of single-dose GO, during induction, did not lead to a higher remission rate or survival benefit, when compared to intensive chemotherapy without GO. Further investigation into the incorporation of GO in the treatment algorithm for CBF-AML is needed.
The system provides a system for a patient to enter historical and/or current information into a data entry device. The system includes intelligent routing so that the patient is guided to meaningful question paths based on answers to prior questions. The system includes graphical and audio capabilities to help the patient provide accurate information. The system contemplates the user entering data prior to meeting with the doctor. When the doctor sees the patient, the doctor already has the patient responses available in full and summary format. The format is consistent from patient to patient and is uniform for all doctors using the system. This allows data to be easily compiled and shared by health professionals. This shared data can aid in indicating epidemics and geographic progressions of ailments and diseases.
Treatment with elranatamab will be initiated using a 2-step-up priming regimen: the initial doses of elranatamab will be 12 mg (Cycle 1 Day 1) and 32 mg (Cycle1 Day 4). Participants should be hospitalized and monitored for toxicity (especially CRS/ICANS) for at least 2 days (\~48 hours) beginning on Cycle 1 Day 1, and for 1 day (\~24 hours) for Cycle1 Day 4. The dose of elranatamab should be increased to 76 mg on Cycle 1 Day 8 as long as the participant meets the redosing criteria or deferred until the criteria are met.

The scheme of administration includes weekly administrations for at least six 4-weeks cycles and, if patients have achieved at least PR (or better) persisting for at least 2 months, the dose interval should be changed from weekly to every other week. Treatment will be scheduled with a response-adapted duration and patients achieving undetectable measurable residual disease and maintained for 12 months will stop therapy. After stopping therapy, and if the patient is in sustained undetectable measurable residual disease for at least 12 months, it would be possible to re-start treatment with elranatamab in case the measurable residual disease will be detectable or relapse from CR will occur. Patients who will not achieve undetectable measurable residual disease sustained for 12 months will receive continuous treatment until progressive disease. In both situations, the occurrence of unacceptable toxicity might result into the treatment discontinuation.
The novel positively charged pro-drugs of peptides and related compounds in the general formula (1) 'Structure 1' were designed and synthesized. The compounds of the general formula (1) 'Structure 1' indicated above can be prepared by standard peptide synthesis protocols. The positively charged amino group of the pro-drug of peptides not only makes the drugs soluble in water, but also bonds to the negative charge on the phosphate head group of membranes and pushes the pro-drug into the cytosol. The lipophilic portion (by modification of the polar groups with lipophilic alkyl groups) of the prodrugs will facilitate the entering of the drugs into the skin membrane. The results suggest that the pro-drugs diffuses through human skin ~100-1000 times faster than do peptides and related compounds. In plasma, more than 40% of these pro-drugs can change back to the parent drugs in a few minutes. The prodrugs can be used medicinally in treating any peptides and related compounds-treatable conditions in humans or animals. The prodrugs can be administered transdermally for any kind of medical treatments and avoid proteolysis by proteolytic enzymes in the GI tract. Controlled transdermal administration systems of the prodrug enables peptides and related compounds to reach constantly optimal therapeutic blood levels to increase effectiveness and reduce the side effects of peptides and related compounds. Another great benefit of transdermal administration of these pro-drugs is that administering medication, especially to children, will be much easier.
Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
Instruct patients to read the "Instructions for Use" carefully for complete directions on how to properly dose and administer ONFI oral suspension.

ONFI Tablet Oral Administration   
ONFI tablets can be taken with or without food.  
ONFI tablets can be administered whole, broken in half along the score, or crushed and mixed in applesauce.

ONFI Oral Suspension Oral Administration   
ONFI oral suspension can be taken with or without food [see Clinical Pharmacology (12.3)].

Shake ONFI Oral Suspension well before every administration. When administering the oral suspension, use only the oral dosing syringe provided with the product. Each carton includes two syringes, but only one syringe should be used for dosing. The second oral syringe is reserved as a replacement in case the first syringe is damaged or lost. Insert the provided adapter firmly into the neck of the bottle before first use and keep the adapter in place for the duration of the usage of the bottle. To withdraw the dose, insert the dosing syringe into the adapter and invert the bottle then slowly pull back the plunger to prescribed dose. After removing the syringe from the bottle adapter, slowly squirt ONFI Oral Suspension into the corner of the patient's mouth. Replace the cap after each use. The cap fits over the adapter when the adapter is properly placed. See ONFI Oral Suspension "Instructions for Use" for complete instruction on how to properly dose and administer the ONFI Oral Suspension.
Heart Failure with Preserved Ejection Fraction (HFpEF) is a major and common cardiovascular condition with widely variable clinical outcomes. Pulmonary hypertension (PH) often co-exists with HFpEF and tends to affect patient outcomes; this study aims to identify the impact of PH on the clinical outcome of patients admitted to the hospital with acute HFpEF exacerbations. We analyzed data from the National Inpatient Sample between 2016 and 2020, focusing on 464,438 acute HFpEF exacerbation hospitalizations. Outcomes were compared between those with PH (27.1 %) and those without PH (72.9 %). HFpEF hospitalizations with PH exhibited elevated in-hospital mortality (adjusted odds ratio [aOR]: 1.20, 95 % confidence interval [95 CI]: 1.08-1.31, P < 0.05), prolonged length of stay (adjusted β: 0.90 days, P < 0.05), and increased overall costs (adjusted β: $2,858, P < 0.05). Furthermore, HFpEF hospitalizations with PH demonstrated higher rates of atrial fibrillation, ventricular tachycardia, right ventricular failure, and conduction abnormalities. This population also displayed an increased incidence of acute hypoxic respiratory failure, necessitating increased non-invasive and mechanical ventilation. The co-existence of PH in HFpEF presents an increased risk of mortality and morbidity, with higher healthcare costs and the need for ventilatory support, in addition to higher risks of cardiovascular and pulmonary complications. Therefore, an early diagnosis of PH in patients with HFpEF is crucial, and further research is required to determine appropriate management.
Hyperlipidemia is very harmful and easy to cause atherosclerosis. Atherosclerosis is the main factor of carotid atherosclerosis. Carotid atherosclerosis and plaque are usually the characteristic manifestations of atherosclerosis. Carotid arteriosclerosis is closely related to stroke, and carotid arteriosclerosis, rupture and detachment of carotid plaques, carotid stenosis and occlusion can all lead to the occurrence of cerebrovascular events. Early detection and evaluation of hyperlipidemia with carotid atherosclerosis by various means can effectively reduce the risk of cardiovascular and cerebrovascular diseases. In order to better serve the vast number of patients, Professor Wang Lei has developed ShenJu granules based on traditional Chinese medicine prescriptions and years of clinical experience. Compared to decoction, ShenJu granules have a higher concentration, are more convenient to carry, and are easy to absorb. They have received unanimous praise from patients in clinical applications.